initi coverag
wave wave initi coverag
launch pharma servic posit view
initi coverag four contract research organ
iclr one contract develop manufactur organ
 posit sector view start industri stori
compel back rapidli progress scienc permiss regulatori
environ massiv tam invest continu flood drug
develop growth rate mid-singl digit per year top rise tide
increas proport invest outsourc pharma servic
org illustr clinic develop spend conduct in-hous
number shrunk increas complex
scienc difficulti find retain trial enrolle nich diseas
higher proport smaller biotech compani research need
drive effici drug develop process drive phenomenon
suspect driver continu acceler lead increas outsourc
penetr disproportion
organ global reach estim industri growth
next sever year suspect larger player grow slightli faster pace
due share gain
robust fund environ emerg biotech
key driver drug develop outsourc penetr continu
increas share spend conduct emerg biotech
compani oppos larg pharma biotech compani often
small coupl doctor toil away singl anonym lab compani
infrastructur conduct clinic trial
typic capit build even want make
help nut bolt trial protocol design project manag
clinic site select patient recruit retent etc cdmo
help formul develop product essenti long
journey preclin safeti efficaci test gruel time-
consum fda approv process way commerci market
pharmaceut research manufactur america estim develop
spend increas mid-high singl digit annual outpac low-mid
singl digit project larg pharma spend fund larg part
on-going ventur capit invest flow biotech high-
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
risk/high-reward natur lend well ventur capit seen
record in-flow back longest bull market histori
perhap biggest recipi receiv worth vc fund
though slight step-down biotech
year cash hand much end flow
 pharma servic org
part growth rate develop spend biotech
well propens outsourc buy rate whose
clinic network propel above-market growth
also buy rate charl river charl river best-in-class asset
early-stag drug develop market benefit biotech
fund environ continu grow quickli vc-fund biotech
look expert early-stag research race get drug
clinic stage ultim commerci market
took year sequenc first human genom today
get genom map two day remark speed
scientist understand human bodi progress pave
way new subset drug target much smaller portion
popul blockbust old addit mani drug cure
diseas rather improv qualiti life actual erad
diseas fda deem drug orphan drug eas
pathway approv wave pdufa fee give tax credit
manufactur product led fda approv success rate
dwarf indic
also led massiv price tag averag orphan drug cost
singl year treatment rise believ
price tag drug continu scientif advanc rel easi
regulatori pathway ensur continu focu find treatment
downsid howev orphan drug develop difficulti
patient recruit caus trial last twice long phase i-iii
non-orphan drug trial phenomenon led continu share gain
larger whose global capabl give unparallel access potenti
trial enrolle particular think iqvia first-class data warehous
analyt capabl posit continu take share along
continu growth real-world evid busi make iqvia top pick
pharma servic space also like icon hold rate share
compani face renew largest custom summer
also face potenti revenu growth slowdown deriv bristol-my
acquisit celgen
also hold rate share lead also
continu grow quickli especi best-in-class cell gene therapi
biolog manufactur capabl howev stock trade all-tim
high multipl think posit larg price share
initi also function transfer coverag iqvia charl river
icon cover lueder georg hill continu cover
mco pharmaci drug wholesal healthcar technolog compani
coverag univers
wave wave initi
coverag
intern use
initi one pre-clin cro three late phase
iclr one
contract research organ expert clinic
trial logist employ pharma compani look
discov promis molecul get molecul
gruel regulatori approv process quickli
build clinic site select manag patient
recruit retent
contract pharma help physic design
manufactur drug
studi method develop commerci
industri stori compel
rel immun regulatori risk
though rise tide lift boat element
fastest grow part market
overweight exposur orphan drug biolog
benign regulatori environ demand/suppli
dynam make area particularli attract
iqvia top pick pharma servic space industri
bellweth differenti offer drive iqvia
grow market share greater penetr custom wallet
charl river industry-lead earli drug develop
also one favorit name
attract clinic develop lab offer
target right custom segment biotech right custom
icon hold rate posit return
out-performance driven scientif advanc permiss regulatori
environ increas outsourc pharma
bloomberg financ llp price
signific industri tailwind drive growth
next sever year larg continu take share
emerg biotech spend grow faster larg
money pour biotech effect money pour servic
compani given biotech propens outsourc
vc fund quarterli basi deal
public market remain hungri biotech exposur
view vc money continu pour biotech time
exit get shorter therebi increas irr investor
time exit like continu shorten view fda
encourag innov permiss regulatori environ
drug develop pipelin strong get
pre-clin drug indic strong line-of-sit
activ studi grow rapid pace
studi abroad domest
see trend favor global pharma servic compani
expens smaller nich player
novel drug approv come year could
orphan drug drug design treat diseas affect small
part popul huntington diseas al muscular
regulatori organ eas pathway approv
orphan drug order incentiv research area
perk includ tax credit pdufa fee
orphan drug expens non-orphan drug due
smaller patient popul complex scienc involv
scientif expertis clinic trial network
pharma servic compani play particularli import role
fda approv novel drug deem
orphan statu approv orphan drug
orphan drug sale set grow next four year due
scientif advanc legisl initi massiv price tag
orphan drug expens
price tag less like face regulatori pressur given theyr
typic drug treat specif diseas state
success rate orphan drug trial much higher
rel high success rate yet anoth reason orphan drug
spend like take market share
phase i-iii orphan drug trial take long phase i-iii
often multipl product compet first
emphasi speed make outsourc attract
difficulti patient recruit retent largest driver
prolong trial
orphanet journal diseas
smaller biotech take share market
competitor outsid top pharma compani set take
share orphan drug market
like increas proport that outsourc
orphan drug posit take greater share
develop pipelin
lead commerci share growth long-
increasingli global footprint orphan drug favor pharma servic
compani global footprint
world evid rwe drug data collect outsid
context tradit clinic trial
rwe becom larg part safeti efficaci coverag
propel better technolog analyt techniqu
pharma servic compani use posit data aggreg
analyz provid support later stage clinic trial
iqvia peg market opportun current
outsourc
expect market grow low doubl digit regul get
increasingli comfort altern sourc data payer
seek efficaci data make coverag decis
world evid grow import
pharma execut survey deloitt rank rwe
import extrem import
view rwe use across lifetim drug
clinic trial recruit post-trial approv
deloitt rwe benchmark survey pharmaceut execut
world evid grow import
exec survey implement pilot discuss
value-bas contract vbc payer
expect rwe grow import innov expens
drug continu come market
deloitt rwe benchmark survey pharmaceut execut
ancillari sourc rwe grow import
payer manufactur increasingli use sourc data
rwe grow
deloitt rwe benchmark survey pharmaceut execut
earli day virtual trial
wearabl rwe also enabl prolifer virtual
trial research particip particip
home
view lead margin accret long-term
site mainten expens
howev accord isr survey drug manufactur
earli day opportun
cro tam subset clinic develop spend
larg pharma grow faster sale
despit worri slowdown larg pharma continu spend
greater share sale
domest spend privat public
addit privat sourc nih help fund scienc
ultim translat commerci viabl drug
expect nih fund hold steadi potenti grow low sd
despit strength spend like deceler
emerg biotech becom ever-mor import drug
 spend highest phase
 spend function give investor idea rel size
phase
pre-clin stage led charl river covanc wuxi
fragment overal
clinic stage concentr hand global player
overal fragment
book outpac revenu larg cro
book-to-bil substanti enough off-set occasion project
cancel indic backlog grow
mean cro like set take market share
view global continu take share nich
player due advantag scale global reach
faster larg pharma
emerg biotech set grow spend quickli
dispos larg pharma outsourc
share set grow
biotech drug grow pipelin
larg pharma effect outsourc biotech
subsequ outsourc pharma servic compani
outsourc continu grow
result outsourc increas sinc trend
dont see slow
larg pharma continu merg buy smaller
often integr activ includ ration drug
ventur capit fund dri
suspect market year visibl outsourc
demand biotech compani base current fund
drug price reform stringent polici fda market
downturn among number potenti caus
pharma begin insourc
view rise small biotech lack infrastructur
conduct clinic trial superior patient recruit
capabl make unlik
slow-down biotech vc
execut lt growth
margin expans target
expos larg pharma
acquir smid-cap biotech
risk thesi
risk thesi includ market pull-
back could weaken biotech ipo
incent thu vc fund
challeng integr variou
acquisit made
vc fund still
second highest year record also
biotech custom year
cash hand
clear line-of-sight
continu acquir fast-grow
asset work strateg within
portfolio cut unalloc
corpor cost drive effici
recent acquisit citoxlab
custom repres
revenu also acquir
compani often want
disrupt research process
acquir often lead
outsourc benefit
initi coverag share buy rate
price target view clear market leader
earli stage drug develop believ take
advantag privileg market posit continu
drive organ growth make smart tack-on acquisit
drive margin expans three segment
price target share ep estim
target multipl price-to-earnings multipl
crl averag premium think premium warrant
given favor current tailwind early-stag drug develop
bloomberg financ lp db estim share price
target
mid-
ep growth rate higher sale growth rate
least low
upsid valuat base price-to-earnings multipl appli ep
estim greater base case ep better ep growth could
driven acceler early-stag drug develop spend continu
synergi recognit recent acquisit
downsid valuat base price-to-earnings multipl appli ep
estim lower base case ep wors ep growth could
driven weak rm due corona viru fallout delay spend
charl river laboratori full servic early-stag contract research organ
cro compani built upon core compet laboratori anim medicin
scienc develop discoveri safeti assess servic
laboratori practic glp non-glp support client target identif
non-clin develop also offer suit product servic
support client manufactur activ product servic enabl client
creat flexibl drug develop model
two recent cell gene
therapi acquisit prudent use
posit
benefit pharma outsourc
share warrant trade histor
high price-to-earnings basi
risk thesi
upsid risk thesi includ industri
tailwind solid execut continu
downsid risk includ slowdown
ye gt massiv opportun
demand growth thoroughli
manufactur masthercel
steep multipl like
acceler organ growth rate
believ posit
well build manufactur
capabl take time capit
intens think larg cdmo
like serv key role
ye believ limit
near-term upsid share given
initi coverag share hold rate
price target view share lead
uniqu asset rapidli grow biolog gt
space well uniqu manufactur capabl
wide varieti small molecul medic though
recogn catal favor outlook view priced-into
share limit near-term upsid view
price target share ep estim
target multipl price-to-earnings multipl
ctlt averag premium think premium
warrant given favor current tailwind biolog manufactur
bloomberg financ lp db estim share price
upsid valuat base price-to-earnings multipl appli ep
estim higher base case ep better ep growth could
driven biolog pipelin growth beat expect take share cell
downsid valuat base price-to-earnings multipl appli ep
estim lower base case ep wors ep growth could
driven unforeseen custom insourc slowdown biolog develop
global provid advanc deliveri technolog develop
solut drug biolog consum health product compani oral
inject gene therapi respiratori deliveri technolog provid solut across
pharmaceut industri includ small molecul protein gene therapi
biolog consum health product expertis product develop
help client bring product market faster includ nearli half new drug
product approv food drug administr last decad
earningstopreferredsharehold
earningstopreferredsharehold
iclr disadvantag posit
given relianc
iclr revenu
bmy/celg merger
iclr improv backlog
risk thesi
strategi allow take develop
share renew leav
conced price renew
ye expand
relationship
contract set renew
summer could includ margin
iclr work
year relationship celg
well could revenu growth
headwind combin
could also long-term growth
trend
tough
improv diseas get ever-
target make patient
face issu well may come
territori
initi coverag iclr share hold rate
price target debt rapid top-lin growth
steadi margin iclr plenti like howev
somewhat cautiou share face contract renew
largest custom summer could advers
affect larg pharma consolid often put
work hold
price target iclr share ep estim
target multipl price-to-earnings multipl in-lin
iclr averag premium though valu comp modest
premium due broad industri tailwind cautiou iclr share
given custom concentr
bloomberg financ lp db estim share price
upsid valuat base price-to-earnings multipl appli ep
estim higher base case ep better ep growth could
driven maintenance/improv current margin largest custom
grow spend mid-siz pharma icon key custom base
downsid valuat base price-to-earnings multipl appli ep
estim lower base case ep wors ep growth could
driven tough negoti largest custom slow spend given
icon public limit compani clinic research organ provid
outsourc develop servic pharmaceut biotechnolog medic
devic industri compani special strateg develop manag
analysi program support everi stage clinic develop process
compound select phase i-iv clinic studi compani earn revenu
numer servic custom includ clinic trial manag
consult contract staf laboratori servic
gross prof
revenu
provis incom tax
net incom attribut nci
net come attrib tab icon
nci adjust redempt amount
ni attri tab le icon cl nci
ga ep clu es nci ad ju stmen
 -ga ps ex clu es nci ad ju stmen
 eig ted vg sh are ou tstan
cash equival
avail sale invest
prepay current asset
properti plant equip net
invest equity-long term
payment account
credit line loan facil
commit conting
accumul comprehens
 low op eratin act iviti
loss dispos properti plant equip
amort oper right-of-us asset
amort intang
amort govern grant
interest short term invest
interest non-curr oper leas liabil
gain re-measur financi asset
amort interest rate hedg
amort financ cost
ch es asset liab ilit
receiv
prepay current asset
non-curr asset
payment account
current liabil
non-curr liabil
net cash rovid ed op erat act iv iti
 low vestin act iviti
purchas properti plant equip
purchas subsidiari undertak
acquir subsidiari undertak
purchas avail sale invest
sale avail sale invest
purchas invest equiti long term
net cash sed estin activit
 low cin act iviti
proce exercis equiti compens
repurchas ordinari share
net cash sed fin cin activit
effect exchang rate movement
net increas cash
begin period
end period
iqv smart trial offer help
gain market share
share industri leader veeva
abl expand ebitda
risk thesi
risk thesi includ industry-wid
drug develop slowdown failur
core-pow solut drive top-
view iqv unmatch
commerci data analyt
capabl give differenti
cro competit year
quintiles/im merger
top pharma compani use
platform carri solut veeva
old platform
allow take share
give price trend see
view invest
phase take wallet share across
custom base ebitda margin
wont expand roi
invest worth
initi coverag share buy rate
price target view best-in-class asset
pharma servic space given broad industry-lead
capabl patient recruit commerci data analyt
rwe believ iqv smart trial solut matur
next year high oper margin flow
margin expans consolid entiti
price target share ep estim
target multipl price-to-earnings multipl
iqv averag premium think premium warrant
given iqvia innov clinic commerci offer continu
bloomberg financ lp db estim share price
upsid valuat base price-to-earnings multipl appli ep
estim higher base case ep better ep growth could
driven margin core-off flow bottom-lin take
share
downsid valuat base price-to-earnings multipl appli ep
estim lower base case ep wors ep growth could
driven gener slowdown develop spend higher new custom
implement cost expect
iqvia provid advanc analyt technolog solut contract research
servic global life scienc industri iqvia appli human data scienc
enabl compani creat new approach clinic develop
commerci speed innov acceler improv healthcar
revenu
revenu
sell gener administr
revenu
revenu
loss extinguish debt
incom incom tax equiti
incom equiti earn unco
equiti earn unconsolid affi
net incom attribut non-controlling
net incom attribut iqvia
cash equival
account receiv unbil servic net
current asset receiv
properti equip net
invest debt equiti secur
invest advanc unconsolid affili
deposit asset
account payabl accru expens
current portion long-term debt oblig held und
long-term debt oblig held capit leas le
accumul comprehens incom
equiti attribut iqvia sharehold
equiti attribut non-controlling interest
total liabil sharehold deficit
depreci amort
amort debt issuanc cost discount
amort commerci right royalti
sale busi properti equipmen
impair long-liv asset
loss earn unconsolid affili
loss invest net
provis benefit defer incom tax
excess incom tax benefit stock option exer
chang oper asset liabil
account receiv unbil servic
prepaid expens asset
account payabl accru expens
incom tax payabl liabil
net cash provid oper activ
proce issuanc debt
payment debt issuanc cost
repay debt
princip payment capit leas oblig
issuanc common stock
repurchas common stock
repay sharehold loan
excess incom tax benefit stock option exer
invest non-controlling interest net
dividend paid common sharehold
net cash use financ activ
effect foreign currenc exchang rate chang
net chang cash
acquisit properti equip softwar
acquisit busi net cash acquir
proce disposit properti equipm
paid termin interest rate swap
matur held-to-matur secur
purchas equiti secur
proce sale equiti secur
balanc divest deconsolid ph
invest advanc unconsolid
payment made proce sale invest
purchas invest
proce invest
chang restrict cash net
net cash use invest activ
ppd biotech offer allow
risk thesi
risk thesi includ failur
differenti biotech
offer competit intensifi
burden heavi debt load rate
ye abil offer top-notch
lab cro servic biotech client
site network tailor specif
idiosyncrat need small biotech
allow gain share among
fastest grow part market
patient recruit commonli cite
pharma biggest pain point
network give look potenti
clinic trial particip
allow custom enrol
ye though lab make
revenu suspect gene
therapi expertis allow
continu outpac clinic
initi coverag share buy rate
price target view high-qual cro
intens focus solv key custom pain-point patient
recruit studi start-up also view biotech
market gimmick think allow
compani take share among industri fastest grow
price target share ep estim
target multipl price-to-earnings multipl in-
line valu peer think well-posit
address custom pain point particularli patient recruit expect
strength allow take share
bloomberg financ lp db estim share price
upsid valuat base price-to-earnings multipl appli ep
estim higher base case ep better ep growth could
driven outsiz success biotech cross-sel lab/clin develop
downsid valuat base price-to-earnings multipl appli ep
estim lower base case ep wors ep growth could
driven stall custom project slowdown develop spend
lead provid drug develop servic biopharmaceut
industri focu help custom bring new medicin patient global
compani provid comprehens suit clinic develop laboratori
servic pharmaceut biotechnolog medic devic govern organ
industri particip
servic revenu
op erat exp en se
revenu
revenu
revenu
total op erat ex en se
op erat ome ga
come oss con ti op
equiti loss uncon affili
net come -con trol
net come
net incom loss nci
sponsor fee relat cost
sever
loss gain investmnet
chang account standard
net incom loss nci
net come
tax effect adjust
tax rate adjust
mi on exc ept ep
properti equip net
li ab li
payabl investig
total cu rren iab es
fair valu hedg transact
total sh areh ol er eq
total ab il sh areh old er eq
depreci amort
equiti method fair valu invest
ch es op eratin asset li ab il iti
advances/pay investig
 ow rom vestin activ es
 ow rom ci acti viti
net proce debt borrow
payment debt financ cost
net issuance/repurchas stock
fin ci cash ow
ch cash
beg
